Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience

被引:107
作者
Rossi, P
Salvatori, FM
Fanelli, F
Bezzi, M
Rossi, M
Marcelli, G
Pepino, D
Riggio, O
Passariello, R
机构
[1] Policlin Umberto 1, Dept Radiol Sci, I-00161 Rome, Italy
[2] Policlin Umberto 1, Dept Gastroenterol, I-00161 Rome, Italy
关键词
hypertension; portal; liver; interventional procedures; shunts; portosystemic; stents and prostheses; venography;
D O I
10.1148/radiol.2313030349
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To prospectively evaluate the use of a recently developed expanded polytetrafluoroethylene (PTFE)-covered nitinol stent-graft in preventing the need for repeated intervention after transjugular intrahepatic portosystemic shunt (TIPS) creation. MATERIALS AND METHODS: Fifty-three consecutive patients underwent TIPS procedures between January 2000 and February 2002. Minimum patient follow-up was 9 months (mean, 16.3 months). Fifty-six stent-grafts were implanted in 53 patients; eight of the devices were 8 mm in diameter and 48 were 10 mm in diameter. The stent length varied from 4 to 7 cm. Indications for the procedure included recurrence of bleeding after sclerotherapy (28 patients with cirrhosis, one patient without), refractory ascites or hydrothorax (21 patients with cirrhosis, one patient without), and Budd-Chiari syndrome (two patients). RESULTS: A technical success rate of 100% was obtained, with an early clinical success rate of 96.2%. During the follow-up period, the recurrence rate was 3.4% (one of 29 patients) for bleeding and 9.0% (two of 22 patients) for ascites. Shunt malfunction occurred in nine of 53 patients (16.9%); in one of these nine patients, shunt occlusion was evident after revision, and a parallel shunt was created. The 1-year primary and secondary patency rates were 83.8% and 98.1%, respectively. In this series, the incidence of encephalopathy (included even as a single short-lived episode) was 47.1% (25 of 53 patients). The 30-day mortality rate was 3.8% (two of 53), and the late mortality rate was 17.3% (eight of 46), excluding seven patients who underwent transplantation. CONCLUSION: The new PTFE-covered nitinol stent-graft used appears to be excellent in preventing the need for repeated interventions. A primary patency rate of 83.8% and a secondary patency rate of 98.1% were achieved. (C) RSNA, 2004.
引用
收藏
页码:820 / 830
页数:11
相关论文
共 37 条
[1]   Stent-grafts for de novo TIPS:: Technique and early results [J].
Andrews, RT ;
Saxon, RR ;
Bloch, RD ;
Petersen, BD ;
Uchida, BT ;
Rabkin, JM ;
Loriaux, MM ;
Keller, FS ;
Rösch, J .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1999, 10 (10) :1371-1378
[2]   Transjugular intrahepatic portosystemic shunt (TIPS): Current status and future possibilities [J].
Bilbao, JI ;
Quiroga, J ;
Herrero, JI ;
Benito, A .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2002, 25 (04) :251-269
[3]   Retrospective comparison of the patency of wallstents and Palmaz long-medium stents used for TIPS [J].
Borsa, JJ ;
Fontaine, AB ;
Hoffer, EK ;
Bloch, RD ;
Tong, E ;
Kuhr, CS ;
Kowdley, KV ;
Schmiedl, UP .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2000, 23 (05) :332-339
[4]   Clinical events after transjugular intrahepatic portosystemic shunt:: Correlation with hemodynamic findings [J].
Casado, M ;
Bosch, J ;
García-Pagán, JC ;
Bru, C ;
Bañares, R ;
Bandi, JC ;
Escorsell, A ;
Rodríguez-Láiz, JM ;
Gilabert, R ;
Feu, F ;
Schorlemer, C ;
Echenagusia, A ;
Rodés, J .
GASTROENTEROLOGY, 1998, 114 (06) :1296-1303
[5]   Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: Initial experiences with a polytetrafluoroethylene-covered nitinol endoprosthesis [J].
Cejna, M ;
Peck-Radosavljevic, M ;
Thurnher, SA ;
Hittmair, K ;
Schoder, M ;
Lammer, J .
RADIOLOGY, 2001, 221 (02) :437-446
[6]   Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage - A randomized, controlled trial [J].
Cello, JP ;
Ring, EJ ;
Olcott, EW ;
Koch, J ;
Gordon, R ;
Sandhu, J ;
Morgan, DR ;
Ostroff, JW ;
Rockey, DC ;
Bacchetti, P ;
LaBerge, J ;
Lake, JR ;
Somberg, K ;
Doherty, C ;
Davila, M ;
McQuaid, K ;
Wall, SD .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (11) :858-+
[7]  
CONN HO, 1991, HEPATOLOGY, V13, P902, DOI 10.1002/hep.1840130517
[8]   Transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension using memotherm stents: A prospective multicenter study [J].
Domagk, D ;
Patch, D ;
Dick, R ;
Grosso, M ;
Rousseau, H ;
Otal, P ;
Goffette, P ;
Heinecke, A ;
Drees, M ;
Domschke, W ;
Menzel, J .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2002, 25 (06) :506-512
[9]   Transjugular intrahepatic portosystemic shunts: Accuracy of Doppler US in determination of patency and detection of stenoses [J].
Feldstein, VA ;
Patel, MD ;
LaBerge, JM .
RADIOLOGY, 1996, 201 (01) :141-147
[10]   Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage [J].
García-Villarreal, L ;
Martínez-Lagares, F ;
Sierra, A ;
Guevara, C ;
Marrero, JM ;
Jiménez, E ;
Monescillo, A ;
Hernández-Cabrero, T ;
Alonso, JM ;
Fuentes, R .
HEPATOLOGY, 1999, 29 (01) :27-32